1. Home
  2. REFR vs BRNS Comparison

REFR vs BRNS Comparison

Compare REFR & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Research Frontiers Incorporated

REFR

Research Frontiers Incorporated

HOLD

Current Price

$0.55

Market Cap

21.6M

Sector

Miscellaneous

ML Signal

HOLD

Logo Barinthus Biotherapeutics plc

BRNS

Barinthus Biotherapeutics plc

N/A

Current Price

$0.64

Market Cap

24.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
REFR
BRNS
Founded
1965
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.6M
24.1M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
REFR
BRNS
Price
$0.55
$0.64
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
54.3K
39.7K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,488,642.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.51
52 Week High
$2.70
$2.91

Technical Indicators

Market Signals
Indicator
REFR
BRNS
Relative Strength Index (RSI) 37.03 44.89
Support Level $0.48 $0.56
Resistance Level $0.83 $0.75
Average True Range (ATR) 0.06 0.05
MACD 0.00 -0.01
Stochastic Oscillator 41.35 27.25

Price Performance

Historical Comparison
REFR
BRNS

About REFR Research Frontiers Incorporated

Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.

About BRNS Barinthus Biotherapeutics plc

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

Share on Social Networks: